| Literature DB >> 28079131 |
Junrui Pei1,2, Bingyun Li1,2, Yang Liu1,2, Xiaona Liu1,2, Mang Li1,2, Yanru Chu1,2, Qing Yang1,2, Wei Jiang1,2, Fuxun Chen1,2, Gottfried M Darko1,2, Yanmei Yang1,2, Yanhui Gao1,2.
Abstract
Brick tea skeletal fluorosis is still a public health issue in the north-western area of China. However its pathogenesis remains unknown. Our previous study reveals that the severity of skeletal fluorosis in Tibetans is more serious than that in Kazaks, although they have similar fluoride exposure, suggesting the onset of brick tea type skeletal fluorosis might be genetically influenced. Here we show that MMP-2 rs2287074 SNP (G/A), but not rs243865, was associated with Brick tea type fluorosis in Tibetans and Kazaks, China. The trend test reveals a decline in probability for skeletal fluorosis with increasing number of A alleles in Tibetans. After controlling potential confounders, AA genotype had about 80 percent lower probability of developing skeletal fluorosis than GG genotype in Tibetans (odds ratio = 0.174, 95% CI: 0.053, 0.575), and approximately 53 percent lower probability in Kazaks (odds ratio = 0.462, 95% CI: 0.214, 0.996). A meta-analysis shows that the AA genotype had approximately 63 percent lower odds (odds ratio = 0.373, 95% CI: 0.202, 0.689) compared with GG genotype within the two ethnicities. A significant correlation was also found between the genotype of MMP2 rs2287074 and skeletal fluorosis severity. Therefore, the A allele of MMP2 rs2287074 could be a protective factor for brick tea skeletal fluorosis.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28079131 PMCID: PMC5227713 DOI: 10.1038/srep40086
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
The prevalence of skeletal fluorosis and fluoride exposure between Tibetans and Kazaks.
| Viariable | All subjects | Tibetans | Kazaks |
|---|---|---|---|
| n (%) | n (%) | n (%) | |
| n = 598 | n = 308 | n = 290 | |
| Fluoride intake (mg) | 5.985(3.749, 10.102) | 5.895(3.797, 9.495) | 6.142(3.642, 10.759) |
| Urine fluoride (mg/L) | 2.755(1.763, 4.138) | 2.359(1.575, 3.628) | 3.166(2.060, 4.576)* |
| Skeletal fluorosis | |||
| cases | 221(36.96%) | 123(39.9%) | 98(33.8%) |
| controls | 377(63.04%) | 185(60.1%) | 192(66.2%) |
| Skeletal fluorosis severity | |||
| no | 377(63.04%) | 185(60.06%) | 192(66.21%) |
| mild | 150(25.08%) | 68(22.08%) | 82(28.28%) |
| moderate | 43(7.19%) | 32(10.39%) | 11(3.79%)* |
| severe | 28(4.68%) | 23(7.47%) | 5(1.72%)* |
Note: Fluoride intake and urine fluoride were represented as median (P25, P75) and tested by Mann-Whitney U test. Z was 0.294 and 5.359, respectively; the comparison of skeletal fluorosis and skeletal fluorosis severity between the two ethnic groups were performed by Likehood Ratio test. Likehood Ratio was 2.415 and 24.145, respectively.*, compare with Tibetans, P < 0.05.
Association of viariables with skeletal fluorosis was evaluated by bivaiate logistic regression model.
| Variables | Tibetans | Kazaks | ||||
|---|---|---|---|---|---|---|
| Cases (n%) | Controls (n%) | Cases (n%) | Controls (n%) | |||
| n = 123 | n = 185 | n = 98 | n = 192 | |||
| Fluoride intake (mg) | 7.051(4.371, 10.968) | 5.305(3.727, 8.617) | 5.201(3.501, 9.073) | 6.51(3.849, 11.784) | 0.106 | |
| Urine Fluoride (mg/L) | 2.636(1.801, 4.138) | 2.172(1.406, 3.512) | 3.093(1.844, 4.495) | 3.215(2.084, 4.585) | 0.528 | |
| Age (years) | 59 ± 12 | 49 ± 12 | 55 ± 10 | 52 ± 12 | ||
| Gender | ||||||
| female | 59(48%) | 114(61.6%) | 54(55.1%) | 127(66.1%) | 0.066 | |
| male | 64(52%) | 71(38.4%) | 44(44.9%) | 65(33.9%) | ||
| Occupation | ||||||
| herdsman | 101(82.1%) | 152(82.2%) | 0.687 | 1(1.0%) | 1(0.5%) | 0.909 |
| farmer | 0(0%) | 2(1.1%) | 92(93.9%) | 179(93.2%) | ||
| other | 22(17.9%) | 31(16.8%) | 5(5.1%) | 12(6.3%) | ||
| Disposable income per capita (RMB) | ||||||
| income ≤ 1000 | 56(45.6%) | 92(49.73%) | 0.827 | 4(4.1%) | 9(4.7%) | 0.723 |
| 1000 < income ≤ 2000 | 39(31.7%) | 50(27.03%) | 32(32.6%) | 68(35.4%) | ||
| 2000 < income ≤ 3000 | 9(7.3%) | 15(8.11%) | 28(28.6%) | 43(22.4%) | ||
| income > 3000 | 19(15.4%) | 28(15.14%) | 34(34.7%) | 72(37.5%) | ||
| Ca supplement | ||||||
| with | 2(1.6%) | 1(0.5%) | 0.566 | 6(6.1%) | 26(13.5%) | 0.056 |
| without | 121(98.4%) | 184(99.5%) | 92(93.9%) | 166(86.5%) | ||
| Altitude (metre) | 3985(3929, 3985) | 3929(3929, 3985) | 571(552, 571) | 571(552, 571) | 0.705 | |
| MMP-2rs243865 | ||||||
| CC | 88(71.5%) | 136(73.5%) | 0.53 | 59(60.2%) | 107(55.7%) | 0.766 |
| CT | 32(26%) | 41(22.2%) | 34(34.7%) | 74(38.5%) | ||
| TT | 3(2.4%) | 8(4.3%) | 5(5.1%) | 11(5.7%) | ||
| MMP-2rs2287074 | ||||||
| GG | 66(53.7%) | 77(41.6%) | 39(39.8%) | 61(31.8%) | 0.154 | |
| AG | 53(43.1%) | 88(47.6%) | 47(48.0%) | 92(47.9%) | ||
| AA | 4(3.3%) | 20(10.8%) | 12(12.2%) | 39(20.3%) | ||
Note: Age was represented as Mean ± SD; Fluoride intake, urine fluoride and altitude were represented as median (P25, P75). Bold font, p < 0.05.
Association of MMP-2 Rs2287074 with skeletal fluorosis in Tibetans and Kazaks.
| Genotype | Tibetans (n = 308) | Kazaks (n = 290) | ||||
|---|---|---|---|---|---|---|
| Cases | Controls | OR (95% CI)* | Cases | Controls | OR (95% CI)# | |
| n (%) | n (%) | n (%) | n (%) | |||
| n = 123 | n = 185 | n = 98 | n = 192 | |||
| GG | 66(53.7%) | 77(41.6%) | 1(Reference) | 39(39.8%) | 61(31.8%) | 1(Reference) |
| AG | 53(43.1%) | 88(47.6%) | 0.588(0.343, 1.007) | 47(48%) | 92(47.9%) | 0.802(0.468, 1.373) |
| AA | 4(3.3%) | 20(10.8%) | 12(12.2%) | 39(20.3%) | ||
Note: *Adjusted for fluoride intake, urine fluoride, age, gender and altitude. #Adjusted for age. Bold font, p < 0.05.
Pooled estimates of ORs (95% CI) for the association between MMP-2 Rs2287074 and skeletal fluorosis.
| Inheritance model | Cases/controls | OR | 95% CI | I2 | ||
|---|---|---|---|---|---|---|
| All subjects | ||||||
| AG versus GG | 221/377 | 0.741 | 0.52~1.055 | 0.096 | 0% | 0.578 |
| AA versus GG | 0.373 | 0.202~0.689 | ||||
| Age ≤ 45 | ||||||
| AG versus GG | 40/144 | 0.751 | 0.365~1.544 | 0.436 | 0% | 0.937 |
| AA versus GG | 0.165 | 0.020~1.339 | 0.092 | |||
| 45 < age ≤ 65 | ||||||
| AG versus GG | 129/183 | 0.592 | 0.362~0.969 | 31.0% | 0.235 | |
| AA versus GG | 0.403 | 0.191~0.850 | ||||
| Age > 65 | ||||||
| AG versus GG | 52/50 | 1.126 | 0.462~2.744 | 0.794 | 0% | 0.894 |
| AA versus GG | 0.168 | 0.031~0.902 | ||||
The correlation of MMP-2 Rs2287074 with skeletal fluorosis severity.
| Genotype | No | Mild | Moderate | Severe | ||
|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | |||
| n = 377 | n = 150 | n = 43 | n = 28 | |||
| All subjects | ||||||
| GG | 138(36.6%) | 64(42.7%) | 26(60.5%) | 15(53.6%) | −0.151 | <0.01 |
| AG | 180(47.7%) | 71(47.3%) | 16(37.2%) | 13(46.4%) | ||
| AA | 59(15.6%) | 15(10%) | 1(2.3%) | 0(0%) | ||
| Tibetans | ||||||
| GG | 77(41.6%) | 35(51.5%) | 19(59.4%) | 12(52.2%) | −0.148 | <0.01 |
| AG | 88(47.6%) | 29(42.6%) | 13(40.6%) | 11(47.8%) | ||
| AA | 20(10.8%) | 4(5.9%) | 0(0%) | 0(0%) | ||
| Kazaks | ||||||
| GG | 61(31.8%) | 29(35.4%) | 7(63.6%) | 3(60%) | −0.122 | 0.038 |
| AG | 92(47.9%) | 42(51.2%) | 3(27.3%) | 2(40%) | ||
| AA | 39(20.3%) | 11(13.4%) | 1(9.1%) | 0(0%) | ||